

Ali Raza Khaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624311/publications.pdf>

Version: 2024-02-01

69
papers

2,363
citations

516215

16
h-index

223531

46
g-index

70
all docs

70
docs citations

70
times ranked

5687
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
2	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. <i>Cancer Investigation</i> , 2022, 40, 17-25.	0.6	2
3	Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. <i>BJU International</i> , 2022, 129, 168-170.	1.3	3
4	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
5	Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e1-273.e9.	0.8	3
6	Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. <i>European Urology</i> , 2022, , .	0.9	0
7	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.	2.0	16
8	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
9	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
10	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	2.0	26
11	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
12	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	2.8	27
13	Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 227.	3.4	7
14	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. <i>Cancer Investigation</i> , 2021, 39, 21-24.	0.6	1
15	Loose Regulatory Standards Portend a New Era of Imprecision Oncology. <i>Cancer Investigation</i> , 2021, 39, 1-4.	0.6	1
16	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	0.9	13
17	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	0.8	0
18	Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.. <i>Journal of Clinical Oncology</i> , 2021, 39, 22-22.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
20	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 443-443.	0.8	4
21	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 445-445.	0.8	2
22	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-444.	0.8	0
23	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 419-419.	0.8	0
24	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 39-39.	0.8	6
25	Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 33-42.	0.2	3
26	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	0.6	4
27	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9029.	1.6	39
28	Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab193.	0.4	4
29	Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 131-133.	2.6	3
30	Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12035-12035.	0.8	1
31	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.	1.4	7
32	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526.	0.8	0
33	Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1575.	0.8	7
34	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16515-e16515.	0.8	1
35	Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11523-11523.	0.8	1
36	Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4537-4537.	0.8	0

#	ARTICLE	IF	CITATIONS
37	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
38	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
39	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	0.8	1
40	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124728.	2.8	4
41	Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. <i>JCO Oncology Practice</i> , 2021, 17, 583-586.	1.4	7
42	Association of treatment type with patient-reported quality of life in cancer distress screening.. <i>Journal of Clinical Oncology</i> , 2021, 39, 178-178.	0.8	6
43	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.	0.8	6
44	Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020.. <i>Journal of Clinical Oncology</i> , 2021, 39, 135-135.	0.8	0
45	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	2.8	32
46	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e266-e276.	0.9	12
47	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
48	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.2	16
49	Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. <i>Cancer</i> , 2020, 126, 4446-4450.	2.0	7
50	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
51	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.	1.7	6
52	771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. <i>Annals of Oncology</i> , 2020, 31, S594.	0.6	0
53	Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.	1.4	6
54	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , 2020, 31, S1202-S1203.	0.6	11

#	ARTICLE	IF	CITATIONS
55	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
56	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
57	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
58	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2020, 136, 56-58.	0.6	3
59	Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
60	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	2.9	53
61	Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16007-e16007.	0.8	6
62	Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16016-e16016.	0.8	0
63	Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4525-4525.	0.8	1
64	Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 89-89.	0.8	0
65	Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1456-1458.	2.3	2
66	Evaluation of a Resident-Led Project to Decrease Phlebotomy Rates in the Hospital: Think Twice, Stick Once. <i>JAMA Internal Medicine</i> , 2016, 176, 708.	2.6	22
67	Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Hypertension</i> , 2014, 27, 801-810.	1.0	49
68	Nucleic Acid Translocation By Hepatitis C Virus Helicase NS3h Is Dependent on Sugar and Base Moieties. <i>Biophysical Journal</i> , 2010, 98, 12a.	0.2	0
69	The Macroscopic Rate of Nucleic Acid Translocation by Hepatitis C Virus Helicase NS3h Is Dependent on Both Sugar and Base Moieties. <i>Journal of Molecular Biology</i> , 2010, 400, 354-378.	2.0	26